Page last updated: 2024-12-06

1-aminooxy-3-aminopropane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-aminooxy-3-aminopropane, also known as **AOAP**, is a bifunctional molecule that contains both an aminooxy group (-NH2OH) and a primary amine group (-NH2). This unique structure gives it several important properties that make it a valuable tool in research:

**Key Properties:**

* **Aminooxy group:** The aminooxy group is a powerful nucleophile that can react with carbonyl groups (aldehydes and ketones) forming stable oximes.
* **Primary amine group:** This group can react with various functional groups, including carboxylic acids, aldehydes, and ketones, forming amides, imines, and Schiff bases, respectively.

**Importance in Research:**

AOAP is widely used in various research areas, including:

* **Bioconjugation:** It acts as a linker molecule, connecting two different molecules via its reactive groups. This property is crucial for developing:
* **Biocompatible materials:** AOAP can be used to attach bioactive molecules (like enzymes or antibodies) to surfaces or nanoparticles, enabling their controlled delivery or specific targeting.
* **Probes for imaging:** It can be used to create fluorescent or radioactive probes for specific molecules in cells or tissues.
* **Chemical synthesis:** AOAP is a valuable reagent for synthesizing various organic compounds. Its reactivity with carbonyl groups allows for the selective modification of aldehydes and ketones, facilitating the production of new molecules with desired properties.
* **Pharmacology:** AOAP is being explored for its potential therapeutic applications. Its ability to interact with carbonyl groups has shown promise in treating conditions like:
* **Alzheimer's disease:** It can inhibit the formation of amyloid beta plaques, implicated in the disease's progression.
* **Cancer:** It can be used to develop targeted delivery systems for chemotherapy drugs.

**In summary:**

1-aminooxy-3-aminopropane (AOAP) is a versatile bifunctional molecule with a wide range of applications in research and development. Its unique reactivity with carbonyl groups and primary amines makes it an essential tool for bioconjugation, chemical synthesis, and drug discovery.

It is important to note that AOAP is a reagent that should be handled with care. It is often used in low concentrations, and its specific applications require optimization and careful safety protocols.

1-aminooxy-3-aminopropane: polyamine biosyn inhibitor; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65020
CHEMBL ID281021
MeSH IDM0134090

Synonyms (17)

Synonym
98532-00-4
1-aminooxy-3-aminopropane
1-propanamine, 3-(aminooxy)-
o-(3-aminopropyl)hydroxylamine
3-aminooxy-1-aminopropane
XAP ,
o-(3-aminopropyl)hydroxylamine, dihydrochloride
CHEMBL281021 ,
AKOS006348478
bdbm50005719
(apa)o-(3-amino-propyl)-hydroxylamine
3-aminooxy-1-propanamine
gtpl5139
DTXSID20243634
3-(aminooxy)propan-1-amine
Q27074476
EN300-6981930
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Ornithine decarboxylaseRattus norvegicus (Norway rat)IC50 (µMol)0.03500.00040.01770.0350AID150877
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (24)

Assay IDTitleYearJournalArticle
AID279024Growth inhibition of Leishmania donovani AG83 promastigotes transfected with episomal ODC gene construct overproducing ODC2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Antileishmanial effect of 3-aminooxy-1-aminopropane is due to polyamine depletion.
AID279036Reversal of growth inhibition of Leishmania donovani promastigotes at 50 uM after 24 hrs of 1 mM spermidine treatment2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Antileishmanial effect of 3-aminooxy-1-aminopropane is due to polyamine depletion.
AID279025Growth inhibition of Leishmania donovani AG83 amastigotes transfected with episomal ODC gene construct overproducing ODC2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Antileishmanial effect of 3-aminooxy-1-aminopropane is due to polyamine depletion.
AID279018Growth inhibition of wild type Leishmania donovani AG83 amastigotes in J774A.1 after 5 days by MTT method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Antileishmanial effect of 3-aminooxy-1-aminopropane is due to polyamine depletion.
AID279035Reversal of growth inhibition of Leishmania donovani promastigotes at 50uM after 48 hrs of 1 mM putrescine treatment2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Antileishmanial effect of 3-aminooxy-1-aminopropane is due to polyamine depletion.
AID279023Reduction of trypanothione level in Leishmania donovani promastigotes at 50 uM after 48 hrs relative to control2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Antileishmanial effect of 3-aminooxy-1-aminopropane is due to polyamine depletion.
AID279022Reduction of spermidine level in Leishmania donovani promastigotes at 50 uM after 48 hrs relative to control2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Antileishmanial effect of 3-aminooxy-1-aminopropane is due to polyamine depletion.
AID279019Growth inhibition of J774A.1 macrophage cells after 24 hrs by MTT method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Antileishmanial effect of 3-aminooxy-1-aminopropane is due to polyamine depletion.
AID279028Growth inhibition of Leishmania donovani SAG-resistant R1 LV patient isolate promastigotes in J774A.1 cells after 5 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Antileishmanial effect of 3-aminooxy-1-aminopropane is due to polyamine depletion.
AID279026Growth inhibition of Leishmania donovani promastigotes S1 LV patient isolate in J774A.1 cells after 5 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Antileishmanial effect of 3-aminooxy-1-aminopropane is due to polyamine depletion.
AID279030Growth inhibition of Leishmania donovani SAG-resistant R2 LV patient isolate promastigotes in J774A.1 cells after 5 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Antileishmanial effect of 3-aminooxy-1-aminopropane is due to polyamine depletion.
AID279020Inhibition of ODC in Leishmania donovani promastigotes at 50 uM after 48 hrs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Antileishmanial effect of 3-aminooxy-1-aminopropane is due to polyamine depletion.
AID150877Inhibitory activity against Rat liver ornithine decarboxylase (ODC)1992Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8
2-substituted 3-(aminooxy)propanamines as inhibitors of ornithine decarboxylase: synthesis and biological activity.
AID279031Growth inhibition of Leishmania donovani SAG-resistant R2 LV patient isolate amastigotes in J774A.1 cells after 5 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Antileishmanial effect of 3-aminooxy-1-aminopropane is due to polyamine depletion.
AID279033Growth inhibition of Leishmania donovani SAG-resistant GE1 LV patient isolate amastigotes in J774A.1 cells after 5 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Antileishmanial effect of 3-aminooxy-1-aminopropane is due to polyamine depletion.
AID279027Growth inhibition of Leishmania donovani amastigotes S1 LV patient isolate in J774A.1 cells after 5 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Antileishmanial effect of 3-aminooxy-1-aminopropane is due to polyamine depletion.
AID279017Growth inhibition of wild type Leishmania donovani AG83 promastigotes in J774A.1 cells after 72 hrs by MTT method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Antileishmanial effect of 3-aminooxy-1-aminopropane is due to polyamine depletion.
AID279029Growth inhibition of Leishmania donovani SAG-resistant R1 LV patient isolate amastigotes in J774A.1 cells after 5 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Antileishmanial effect of 3-aminooxy-1-aminopropane is due to polyamine depletion.
AID208519Inhibitory activity against Human T24 bladder carcinoma cells1992Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8
2-substituted 3-(aminooxy)propanamines as inhibitors of ornithine decarboxylase: synthesis and biological activity.
AID279032Growth inhibition of Leishmania donovani SAG-resistant GE1 LV patient isolate promastigotes in J774A.1 cells after 5 days2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Antileishmanial effect of 3-aminooxy-1-aminopropane is due to polyamine depletion.
AID279034Reversal of growth inhibition of Leishmania donovani promastigotes at 50uM after 24 hrs of 1 mM putrescine treatment2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Antileishmanial effect of 3-aminooxy-1-aminopropane is due to polyamine depletion.
AID279021Reduction of putrescine level in Leishmania donovani promastigotes at 50 uM for after 48 hrs relative to control2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Antileishmanial effect of 3-aminooxy-1-aminopropane is due to polyamine depletion.
AID279037Reversal of growth inhibition of Leishmania donovani promastigotes at 50 uM after 48 hrs of 1 mM spermidine treatment2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Antileishmanial effect of 3-aminooxy-1-aminopropane is due to polyamine depletion.
AID1345225Human Ornithine decarboxylase (Decarboxylases)1992Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8
2-substituted 3-(aminooxy)propanamines as inhibitors of ornithine decarboxylase: synthesis and biological activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (27.27)18.7374
1990's8 (36.36)18.2507
2000's6 (27.27)29.6817
2010's1 (4.55)24.3611
2020's1 (4.55)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.26 (24.57)
Research Supply Index3.14 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]